Penpulimab Side Effects

Applies to penpulimab: intravenous solution.

General adverse events

The most common adverse reactions when this drug was administered as a single agent (20% or greater) were anemia and hypothyroidism. The most common Grade 3 to 4 laboratory abnormalities (2% or greater) were decreased lymphocytes, increased gamma-glutamyltransferase (GGT), decreased phosphate, decreased sodium, increased AST, increased alkaline phosphatase, decreased hemoglobin, increased bilirubin, increased glucose, increased triglycerides, increased ALT, increased magnesium , and decreased platelets.^[Ref]

Dermatologic

• Very common (10% or more): Rash (11%)^[Ref]

Endocrine

• Very common (10% or more): Hypothyroidism (39%)
• Uncommon (0.1% to 1%): Diabetes^[Ref]

Hematologic

• Very common (10% or more): Decreased albumin (45%), prolonged activated partial thromboplastin time (22%), decreased lymphocytes (43%) decreased hemoglobin (36%), anemia (25%)
• Common (1% to 10%): Decreased platelets^[Ref]

Hepatic

• Very common (10% or more): Increased GGT (34%), increased AST (33%), increased ALT (20%)^[Ref]

Hypersensitivity

• Very common (10% or more): Infusion related reactions (10%)^[Ref]

Immunologic

• Very common (10% or more): Immune-mediated hypothyroidism (19%), immune-mediated rash/dermatitis (12%)
• Common (1% to 10%): Immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hyperthyroidism, immune-mediated hepatitis
• Uncommon (0.1% to 1%): Immune-mediated thyroiditis, immune-mediated nephritis
• Frequency not reported: Immune mediated myocarditis, pericarditis, vasculitis, meningitis, encephalitis, myelitis, myasthenic syndrome/myasthenia gravis, Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy, nerve injury, uveitis, iritis, visual impairment, Vogt-Koyanagi-Harada-like syndrome, pancreatitis, gastritis, duodenitis, myositis/polymyositis, rhabdomyolysis, hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection^[Ref]

Metabolic

• Very common (10% or more): Decreased weight (19%), decreased phosphate (47%), decreased sodium (46%), increased triglycerides (38%), increased alkaline phosphatase (35%), increased glucose (34%), decreased magnesium (28%)^[Ref]

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (25%)^[Ref]

Other

• Very common (10% or more): Pyrexia (15%)^[Ref]

Renal

• Very common (10% or more): Increased creatinine (81%)^[Ref]

Respiratory

• Very common (10% or more): Upper respiratory tract infection (13%), cough (11%)^[Ref]

See also:

Further information

Penpulimab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer